Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia
Open Access
- 1 August 2018
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine
- Vol. 97 (34), e11860
- https://doi.org/10.1097/md.0000000000011860
Abstract
Hypomethylating agents (HMAs) are believed to have reliable efficacy in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Meanwhile, the adverse events of HMAs have become an increasing concern. There is, however, no systematic meta-analysis available to evaluate overall hematologic toxicities for HMAs. In this meta-analysis, we aim to determine the risk of hematologic toxicities in patients treated with HMAs. Relevant studies were identified from PubMed, Embase, Cochrane Library, and the Clinical Trials. gov databases incepted to February 2018. All phase II and III trials meeting the inclusion criteria included adequate safety data. We calculated the relative risk (RR) of high-grade hematologic toxicities (HTEs) with corresponding 95% CI using Review Manager. The incidences of HTEs were also evaluated by R. Heterogeneity was calculated and reported mainly via I2 analyses. A total of 2337 MDS or AML patients from 14 studies were identified in this meta-analysis. The overall incidences of high-grade hematologic toxicities in patients who received HMAs were: 27% of the patients with anemia, 45% with neutropenia, 38% with thrombocytopenia, and 25% with febrile neutropenia, respectively. There was a significantly increased RR of neutropenia and thrombocytopenia using HMAs, in comparison with conventional care regimens (CCR) based on the drug type (decitabine vs azacitidine). We conclude that the use of HMAs are associated with an increased risk of neutropenia and thrombocytopenia in MDS or AML patients, and our results also demonstrate that HMAs exposure does not significantly increase the risk of high-grade anemia, leukopenia, or febrile neutropenia compared with CCR.Keywords
This publication has 57 references indexed in Scilit:
- Base-Pair Resolution DNA Methylation Sequencing Reveals Profoundly Divergent Epigenetic Landscapes in Acute Myeloid LeukemiaPLoS Genetics, 2012
- Functions of DNA methylation: islands, start sites, gene bodies and beyondNature Reviews Genetics, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineProceedings of the National Academy of Sciences of the United States of America, 2010
- DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2010
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndromeCancer, 2007
- The history of cancer epigeneticsNature Reviews Cancer, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986